Author

F. Petralia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Approach:statistical model· 3 Approach:benchmark study· 2 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Assay:proteomics· 2

Frequent Co-Authors

S. Mehandru· 3 shared A. D. Polydorides· 2 shared A. Dunn· 2 shared A. Krek· 2 shared A. Livanos· 2 shared C. Argmann· 2 shared D. Jha· 2 shared F. Cossarini· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

S. Mehandru

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis.

D. Jha, Z. Al-Taie, A. Krek, S. T. Eshghi, A. Fantou, T. Laurent, M. Tankelevich, X. Cao, H. Meringer, A. Livanos, M. Tokuyama, F. Cossarini, A. Bourreille, R. Josien, R. Hou, , S. Mehandru

The paper identifies myeloid cell influx and epithelial cell perturbations in ulcerative colitis, linking them to disease severity and anti-TNF therapy non-response.

bioRxiv · Jun 2, 2023 · PreprintImmunology

Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis

P. Canales-Herrerias, M. Uzzan, A. Seki, R. S. Czepielewski, B. Verstockt, A. Livanos, F. Raso, A. Dunn, D. Dai, A. Wang, Z. Al-taie, J. Martin, H. M. Ko, M. Tokuyama, M. Tankelevich, , S. Mehandru

This study investigates the mechanism of vedolizumab in ulcerative colitis by analyzing immune cell changes in gut-associated lymphoid tissue and shows that targeting GALT is a novel mechanism of action.

bioRxiv · Jan 19, 2023Immunology

Decomprolute: A benchmarking platform designed for multiomics-based tumor deconvolution

S. Feng, A. P. Calinawan, P. Pugliese, P. Wang, M. Ceccarelli, F. Petralia, S. J. Gosline

Decomprolute benchmarks multi-omic tumor deconvolution algorithms using proteogenomic data from CPTAC to improve reproducibility and reusability.

bioRxiv · Jan 5, 2023Cancer Biology

Anti-integrin αvβ6 autoantibodies are a novel predictive biomarker in ulcerative colitis

A. E. Livanos, A. Dunn, J. Fischer, R. C. Ungaro, W. Turpin, S.-H. Lee, S. Rui, D. M. Del Valle, J. J. Julia, G. Martinez-Delgado, M. S. Riddle, J. A. Murray, R. M. Laird, J. Torres, M. Agrawal, , S. Mehandru

This study identifies anti-integrin αvβ6 autoantibodies as a predictive biomarker for ulcerative colitis, showing they precede diagnosis by up to 10 years and correlate with adverse outcomes.

bioRxiv · Nov 21, 2022 · PreprintImmunology

CITEseq analysis of non-small-cell lung cancer lesions reveals an axis of immune cell activation associated with tumor antigen load and TP53 mutations

A. M. Leader, J. A. Grout, C. Chang, B. Maier, A. Tabachnikova, L. Walker, A. Lansky, J. LeBerichel, N. Malissen, M. Davila, J. Martin, G. Magri, K. Tuballes, Z. Zhoa, F. Petralia, , M. Merad

The paper analyzes CITEseq data from NSCLC lesions to identify an immune cell activation module linked to tumor antigen load and TP53 mutations.

bioRxiv · Jul 16, 2020 · PreprintImmunology